172 related articles for article (PubMed ID: 20460445)
1. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
Horton ES; Silberman C; Davis KL; Berria R
Diabetes Care; 2010 Aug; 33(8):1759-65. PubMed ID: 20460445
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
Malloy J; Meloni A; Han J
Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
[TBL] [Abstract][Full Text] [Related]
3. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
[TBL] [Abstract][Full Text] [Related]
4. Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Adv Ther; 2010 Apr; 27(4):223-32. PubMed ID: 20464538
[TBL] [Abstract][Full Text] [Related]
5. [New drugs; exenatide and sitagliptin].
van Bronswijk H; Dubois EA; Pijl H; Cohen AF
Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528
[TBL] [Abstract][Full Text] [Related]
6. Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.
Gudipaty L; Rosenfeld NK; Fuller CS; Gallop R; Schutta MH; Rickels MR
Diabetes Care; 2014 Sep; 37(9):2451-8. PubMed ID: 24969577
[TBL] [Abstract][Full Text] [Related]
7. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
[TBL] [Abstract][Full Text] [Related]
8. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
Niswender K; Pi-Sunyer X; Buse J; Jensen KH; Toft AD; Russell-Jones D; Zinman B
Diabetes Obes Metab; 2013 Jan; 15(1):42-54. PubMed ID: 22862847
[TBL] [Abstract][Full Text] [Related]
9. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
Blonde L; Pencek R; MacConell L
Cardiovasc Diabetol; 2015 Feb; 14():12. PubMed ID: 25645567
[TBL] [Abstract][Full Text] [Related]
10. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.
Rosenstock J; Shenouda SK; Bergenstal RM; Buse JB; Glass LC; Heilmann CR; Kwan AY; MacConell LA; Hoogwerf BJ
Diabetes Care; 2012 May; 35(5):955-8. PubMed ID: 22432107
[TBL] [Abstract][Full Text] [Related]
11. [Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
MMW Fortschr Med; 2009 May; 151(19):50. PubMed ID: 19827447
[No Abstract] [Full Text] [Related]
12. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
13. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
15. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
16. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction.
Mafong DD; Henry RR
Curr Atheroscler Rep; 2008 Feb; 10(1):55-60. PubMed ID: 18366986
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
18. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.
Garg R; Chen W; Pendergrass M
Diabetes Care; 2010 Nov; 33(11):2349-54. PubMed ID: 20682680
[TBL] [Abstract][Full Text] [Related]
19. Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting.
Bhushan R; Elkind-Hirsch KE; Bhushan M; Butler WJ; Duncan K; Marrioneaux O
Diabetes Technol Ther; 2009 Jun; 11(6):353-9. PubMed ID: 19459763
[TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
Iglesias P; Civantos S; Vega B; Pavón I; Guijarro G; Monereo S
Obes Surg; 2015 Mar; 25(3):575-8. PubMed ID: 25589020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
